Trial reportBMC cancer2026
Platinum-free triplet therapy with nab-paclitaxel, S-1, and tislelizumab as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: a phase ii single-arm trial.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPlatinum-based chemoimmunotherapy is used as a first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma under specific regulatory circumstances, but effectiveness is often limited by cumulative toxicity, particularly in older patients and those with stroma-rich metastases.
methodsThis single-arm, phase II trial evaluated the efficacy and safety of a platinum-free triplet regimen as first-line therapy in patients with metastatic or unresectable G/GEJ adenocarcinoma. Participants received intravenous tislelizumab (200 mg, day 1), nab-paclitaxel (100 mg/m², days 1 and 8), and oral S-1 (80–120 mg twice daily, days 1–14) every 21 days. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included overall survival (OS), surgical conversion rate, disease control rate (DCR), and safety.
resultsAmong 43 enrolled patients, the confirmed ORR was 81.4% (95% confidence interval [CI]: 66.60-91.61%) and the DCR was 90.7% (95% CI: 77.86–97.41%). The overall median PFS was 8.6 months (95% CI: 6.10-11.04), and the overall median OS for the ITT population was 20.1 months (95% CI: 17.69–22.45). In subgroup analyses, patients who underwent conversion surgery had significantly longer OS compared with those who did not (median 29.5 months vs. 18.3 months; hazard ratio [HR]: 0.42, 95% CI: 0.20–0.90; P = 0.050). Patients aged ≥ 65 years showed longer PFS (13.7 vs. 7.2 months; HR: 0.39, 95% CI 0.19–0.80; P = 0.006) and OS (29.2 vs. 16.4 months; HR: 0.42, 95% CI 0.20–0.88; P = 0.021) than those aged < 65 years. Eight patients (18.6%) underwent conversion surgery, with 2 achieving pathological complete response. Grade ≥ 3 treatment-related adverse events included neutropenia (9.3%), leukopenia (7.0%), and anemia (2.3%).
conclusionsThis triplet regimen of nab-paclitaxel, S-1, and tislelizumab showed encouraging antitumor activity with a manageable safety profile. These findings warrant further validation in phase III randomized controlled trials, and support this regimen as a potential strategy, especially for older patients who may be less tolerant of platinum-based therapies.
trial registrationChiCTR2200062653 registered August 14, 2022 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.